Amoxicillin

Generic Name: Amoxicillin

Brand Names: Amoxil, Augmentin, Clavulin, Moxatag, Omeclamox, Prevpac, Talicia, Voquezna 14 Day Dualpak 20;500, Voquezna 14 Day Triplepak 20;500;500

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₉N_₃O_₅S

CAS Number: 26787-78-0

Unique Ingredient Identifier: 9EM05410Q9

Background: Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.

Amoxicillin was granted FDA approval on 18 January 1974.

Indication: Amoxicillin alone is indicated to treat susceptible bacterial infections of the ear, nose, throat, genitourinary tract, skin, skin structure, and lower respiratory tract. Amoxicillin is given with calvulanic acid to treat acute bacterial sinusitis, community acquired pneumonia, lower respiratory tract infections, acute bacterial otitis media, skin and skin structure infections, and urinary tract infections. Amoxicillin is given with omeprazole in the treatment of Helicobacter pylori (H. pylori) infection.

Amoxicillin is used in combination with vonoprazan and clarithromycin as co-packaged triple therapy or in combination with vonoprazan as co-packaged dual therapy to treat H. pylori infection in adults.

Associated Conditions: Acute Bacterial Sinusitis (ABS), Acute Otitis Media (AOM), Bacterial Infections, Community Acquired Pneumonia (CAP), Duodenal ulcer caused by helicobacter pylori, Genitourinary tract infection, Helicobacter Pylori Infection, Lower Respiratory Tract Infection (LRTI), Peptic Ulcer With H. Pylori Infection, Sinusitis, Skin and Subcutaneous Tissue Bacterial Infections, Urinary Tract Infection, Acute, uncomplicated Gonorrhea, Ear, nose, and throat infections

Associated Therapies: -

Clinical Trials

Study of Levofloxacin-based Concomitant Therapy for H. Pylori Eradication in Diabetic Patients

Phase 4

Completed

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Pantoprazole
Drug: Amoxicillin
Drug: Metronidazole
Drug: Clarithromycin
Drug: Levofloxacin

First Posted Date: 2015-06-09

Last Posted Date: 2016-09-02

Lead Sponsor: Chung-Tai Wu

Target Recruit Count: 114

Registration Number: NCT02466919

Short-course Antimicrobial Therapy for Paediatric Respiratory Infections

Phase 4

Completed

Conditions: Community-acquired Pneumonia

Interventions: Drug: Amoxicillin
Drug: Placebo

First Posted Date: 2015-03-05

Last Posted Date: 2021-06-08

Lead Sponsor: Hamilton Health Sciences Corporation

Target Recruit Count: 281

Registration Number: NCT02380352

Locations: 🇨🇦
Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
🇨🇦
McMaster Children's Hospital, Hamilton, Ontario, Canada

Randomized Trial of Amoxicillin Versus Placebo for (Fast Breathing) Pneumonia

Not Applicable

Completed

Conditions: Pneumonia
Tachypnea

Interventions: Drug: Placebo
Drug: Amoxicillin

First Posted Date: 2015-02-26

Last Posted Date: 2019-09-16

Lead Sponsor: Aga Khan University

Target Recruit Count: 4000

Registration Number: NCT02372461

Locations: 🇵🇰
PHC at Ibrahim Haidry Goth, Ali Akber Shah Colony, Rerhi Goth, Bhains Colony, Karachi, Sind, Pakistan

The Efficacy of the 7 Days Tailored Therapy as 2nd Rescue Therapy for Eradication of H. Pylori Infection

Not Applicable

Terminated

Conditions: Helicobacter Infection

Interventions: Drug: 14 days empirical bismuth quadruple therapy (Proton pump inhibitor)
Procedure: H. pylori culture and antimicrobial susceptibility testing
Drug: 7 days tailored therapy Proton Pump Inhibitor
Drug: Metronidazole
Drug: Tetracycline
Drug: Moxifloxacin
Drug: tripotassium dicitrate bismuthate
Drug: Amoxicillin

First Posted Date: 2015-02-10

Last Posted Date: 2023-04-13

Lead Sponsor: Seoul National University Bundang Hospital

Target Recruit Count: 370

Registration Number: NCT02359331

Locations: 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of

Study to Compare the Efficacy of Pristinamycin (Pyostacine ®) Versus Amoxicillin in the Treatment of Acute Community Acquired Pneumonia

Phase 4

Terminated

Conditions: Pneumonia

Interventions: Drug: Amoxicillin
Drug: PRISTINAMYCIN XRP7263
Drug: Amoxicillin Placebo
Drug: PRISTINAMYCIN Placebo

First Posted Date: 2015-01-07

Last Posted Date: 2023-05-08

Lead Sponsor: Sanofi

Target Recruit Count: 161

Registration Number: NCT02332577

Locations: 🇫🇷
Investigational Site Number :250010, Grenoble, France
🇫🇷
Investigational Site Number :250029, Avoine, France
🇫🇷
Investigational Site Number :250015, COLOMBES Cedex, France

and more 16 locations